A PESTEL analysis and expert interviews map out all external influences and key actors to pinpoint the political, economic, social and regulatory factors that will shape technology adoption. It then translates stakeholder insights into prioritized technical and usability requirements via targeted questionnaires, ensuring the device meets real-world needs. Building on this, acceptance studies systematically gather and analyze stakeholders feedback to establish clear criteria for end-user buy-in, and a comprehensive cost-effectiveness model compares point-of-care versus conventional CAR-T therapies (including QALYs, long-term follow-ups, Monte Carlo sensitivity analysis, and workflow-driven cost inputs) to guide strategic decision-making.
Afschin is a physician, health economist, and professor of Health Management at the Frankfurt School of Finance & Management. His research focuses on cost-effectiveness analysis, decision modeling, and value-based pricing of pharmaceuticals. Within the EASYGEN project, he is responsible for conducting the health economic evaluation.